The Experts below are selected from a list of 312 Experts worldwide ranked by ideXlab platform
Rodney Sinclair - One of the best experts on this subject based on the ideXlab platform.
-
Chronic telogen effluvium: a study of 5 patients over 7 years.
Journal of the American Academy of Dermatology, 2020Co-Authors: Rodney SinclairAbstract:Chronic telogen effluvium is said to be self-limiting in the long run; the natural history of this condition, however, has not been investigated prospectively. Four women, aged between 18 and 64 years and diagnosed with chronic telogen effluvium between 1996 and 1997, were followed up prospectively for a minimum of 7 years. One (previously reported) woman diagnosed in 1998 developed female pattern Hair loss confirmed on biopsy specimen within 18 months that was partially reversed by spironolactone. The remaining 4 women continued to experience chronic diffuse telogen Hair Shedding that fluctuated in severity. However, serial photography demonstrated no visible reduction in Hair density, and serial scalp biopsy specimen showed no follicular miniaturization. Although 4 out of 5 of our patients showed no tendency toward development of female pattern Hair loss or to spontaneous improvement, further work is required to define the natural history of chronic telogen effluvium and the relative risk of developing female pattern Hair loss.
-
novel shampoo reduces Hair Shedding by contracting the arrector pili muscle via the trace amine associated receptor
Journal of Cosmetic Dermatology, 2019Co-Authors: Maja Kovacevic, Andy Goren, Jerry Shapiro, Mirna Situm, John Mccoy, Andrija Stanimirovic, Sergio Vanogalvan, Rodney SinclairAbstract:BACKGROUND: Approximately 40% of women experience excessive Hair Shedding when washing their Hair. Previously, we have demonstrated that a topically applied alpha1 adrenergic receptor agonist can be used to contract the arrector pili muscle of the follicular unit (ie, produce "goose bumps"), increasing the force required to pluck Hair by as much as 400%. Subsequently, we reported a topical cosmetic solution containing an alpha1 adrenergic receptor agonist that reduced Hair Shedding during brushing by a maximum of 77%. AIMS: In this communication, we explore a novel mechanism to contract the arrector pili muscle. Trace amine-associated receptors (TAAR) have been shown to regulate smooth muscle tone in blood vessels, but have not been reported to be present in the skin. Here, we report on the anti-Shedding efficacy of a shampoo containing a selective TAAR agonist, tyramine hydrochloride. METHODS: A single-blinded crossover study was designed to test the efficacy of the novel shampoo versus placebo in reducing Hairs lost during brushing. RESULTS: In this study, the novel TAAR shampoo reduced Hair Shedding during brushing by 31% in a cohort of 24 women with a maximum reduction of 77%. CONCLUSIONS: A shampoo formulated with a selective TAAR agonist was demonstrated to contract the arrector pili muscle and reduce Hair Shedding subsequent to washing.
-
Novel shampoo reduces Hair Shedding by contracting the arrector pili muscle via the trace amine-associated receptor.
Journal of Cosmetic Dermatology, 2019Co-Authors: Maja Kovačević, Andy Goren, Jerry Shapiro, Mirna Situm, John Mccoy, Andrija Stanimirović, Sergio Vano-galvan, Rodney SinclairAbstract:Approximately 40% of women experience excessive Hair Shedding when washing their Hair. Previously, we have demonstrated that a topically applied α1 adrenergic receptor agonist can be used to contract the arrector pili muscle of the follicular unit (ie, produce "goose bumps"), increasing the force required to pluck Hair by as much as 400%. Subsequently, we reported a topical cosmetic solution containing an α1 adrenergic receptor agonist that reduced Hair Shedding during brushing by a maximum of 77%. In this communication, we explore a novel mechanism to contract the arrector pili muscle. Trace amine-associated receptors (TAAR) have been shown to regulate smooth muscle tone in blood vessels, but have not been reported to be present in the skin. Here, we report on the anti-Shedding efficacy of a shampoo containing a selective TAAR agonist, tyramine hydrochloride. A single-blinded crossover study was designed to test the efficacy of the novel shampoo versus placebo in reducing Hairs lost during brushing. In this study, the novel TAAR shampoo reduced Hair Shedding during brushing by 31% in a cohort of 24 women with a maximum reduction of 77%. A shampoo formulated with a selective TAAR agonist was demonstrated to contract the arrector pili muscle and reduce Hair Shedding subsequent to washing. © 2019 Wiley Periodicals, Inc.
-
styling without Shedding novel topical formula reduces Hair Shedding by contracting the arrector pili muscle
Dermatologic Therapy, 2018Co-Authors: John Mccoy, Maja Kovacevic, Andy Goren, Jerry Shapiro, Mirna Situm, Andrija Stanimirovic, Rodney SinclairAbstract:Approximately 40% of women experience excessive Hair Shedding during styling (e.g., Hair brushing). Previously, we demonstrated that topically applied phenylephrine, a potent a1 adrenergic receptor agonist, can be used to contract the arrector pili muscle of the follicular unit ; thus, increasing the force required to pluck Hair and reducing Shedding during brushing. While demonstrating efficacy, phenylephrine has several drawbacks when applied to the scalp, including the possibility cardiovascular events. We hypothesized that a high concentration of a weak a1 agonist would allow for: (a) rapid penetration through the stratum corneum eliciting a quick response ; (b) a low probability of cardiac adverse events owing to the low receptor binding affinity ; and (c) an efficacy of the weak a1 agonist similar to that of phenylephrine at the local site of application. Accordingly, we developed a novel topical solution, AB-102, containing a high concentration of a weak a1 agonist. Several studies were conducted to test the safety and efficacy of AB-102. In a dose escalating safety study, utilizing a wearable holter monitor, we observed no cardiac or hemodynamic adverse events. In addition, in a controlled efficacy study, AB-102 reduced the number of Hairs shed during brushing by up to 77% (average of 38%).
-
Female pattern Hair loss: a pilot study investigating combination therapy with low‐dose oral minoxidil and spironolactone
International Journal of Dermatology, 2017Co-Authors: Rodney SinclairAbstract:Background Minoxidil and spironolactone are oral antihypertensives known to stimulate Hair growth. Objective To report on a case series of women with pattern Hair loss (PHL) treated with once daily minoxidil 0.25 mg and spironolactone 25 mg. Methods Women newly diagnosed with a Sinclair stage 2–5 PHL were scored for Hair Shedding and Hair density before and after 12 months of treatment with oral minoxidil 0.25 mg and spironolactone 25 mg. Results A total of 100 women were included in this observational pilot study. Mean age was 48.44 years (range 18–80). Mean Hair loss severity at baseline was Sinclair 2.79 (range 2–5). Mean Hair Shedding score at baseline was 4.82. Mean duration of diagnosis was 6.5 years (range 0.5–30). Mean reduction in Hair loss severity score was 0.85 at 6 months and 1.3 at 12 months. Mean reduction in Hair Shedding score was 2.3 at 6 months and 2.6 at 12 months. Mean change in blood pressure was −4.52 mmHg systolic and −6.48 mmHg diastolic. Side effects were seen in eight women but were generally mild. No patients developed hyperkalemia or any other blood test abnormality. Six of these women continued treatment, and two women who developed urticaria discontinued treatment. Limitations Prospective, uncontrolled, open-label observational study. Discussion Once daily capsules containing minoxidil 0.25 mg and spironolactone 25 mg appear to be safe and effective in the treatment of FPHL. Placebo-controlled studies to investigate this further are warranted.
Glynis Ablon - One of the best experts on this subject based on the ideXlab platform.
-
a marine protein based dietary supplement for subclinical Hair thinning loss results of a multisite double blind placebo controlled clinical trial
International Journal of Trichology, 2015Co-Authors: Ronald L Rizer, Thomas J Stephens, James H Herndon, Brian R Sperber, James Murphy, Glynis AblonAbstract:Introduction: Since skin and Hair quality are potent vitality signals, and Hair growth deficiency can cause significant psychological morbidity. In addition to clearly-defined Hair loss disorders, milder forms of Hair thinning or Hair loss appear to be increasingly common, with a suggestion that sub-optimal diets and stressful lifestyles may be involved. Methods: Here we assess the value of a dietary marine-extract based dietary supplement in premenopausal women with subclinical Hair thinning or Hair loss conditions. This multi-site, randomized double-blind, placebo-controlled clinical trial was conducted with impact on Hair Shedding rate and Hair fiber diameter (assessed by phototrichogram) as primary end points upon consumption of the oral supplement compared to a placebo. A total of 96 eligible female subjects were enrolled aged 21-55 years of age from Asian, Caucasian, and Hispanic ethnic backgrounds. Results: This study showed that Hair Shedding was significantly reduced in the first 3-6 months of daily consumption of the oral supplement. Moreover, phototrichogram image analysis revealed a statistically significant increase in the mean vellus-like Hair diameter after 6 months of supplement consumption, when compared to the mean vellus-like Hair diameters measured at baseline. Discussion: These results support the view that a nutritional supplement approach may be useful for women in this age group to deal with subclinical Hair thinning or Hair loss conditions, and those components of this marine extract-based oral supplement may be a useful adjunct.
-
A marine protein-based dietary supplement for subclinical Hair thinning/loss: Results of a multisite, double-blind, placebo-controlled clinical trial
International Journal of Trichology, 2015Co-Authors: Ronald L Rizer, Thomas J Stephens, James H Herndon, Brian R Sperber, James Murphy, Glynis AblonAbstract:Introduction: Since skin and Hair quality are potent vitality signals, and Hair growth deficiency can cause significant psychological morbidity. In addition to clearly-defined Hair loss disorders, milder forms of Hair thinning or Hair loss appear to be increasingly common, with a suggestion that sub-optimal diets and stressful lifestyles may be involved. Methods: Here we assess the value of a dietary marine-extract based dietary supplement in premenopausal women with subclinical Hair thinning or Hair loss conditions. This multi-site, randomized double-blind, placebo-controlled clinical trial was conducted with impact on Hair Shedding rate and Hair fiber diameter (assessed by phototrichogram) as primary end points upon consumption of the oral supplement compared to a placebo. A total of 96 eligible female subjects were enrolled aged 21-55 years of age from Asian, Caucasian, and Hispanic ethnic backgrounds. Results: This study showed that Hair Shedding was significantly reduced in the first 3-6 months of daily consumption of the oral supplement. Moreover, phototrichogram image analysis revealed a statistically significant increase in the mean vellus-like Hair diameter after 6 months of supplement consumption, when compared to the mean vellus-like Hair diameters measured at baseline. Discussion: These results support the view that a nutritional supplement approach may be useful for women in this age group to deal with subclinical Hair thinning or Hair loss conditions, and those components of this marine extract-based oral supplement may be a useful adjunct.
-
a 3 month randomized double blind placebo controlled study evaluating the ability of an extra strength marine protein supplement to promote Hair growth and decrease Shedding in women with self perceived thinning Hair
Dermatology Research and Practice, 2015Co-Authors: Glynis AblonAbstract:An oral marine protein supplement (MPS) is designed to promote Hair growth in women with temporary thinning Hair (Viviscal Extra Strength; Lifes2good, Inc., Chicago, IL). This double-blind, placebo-controlled study assessed the ability of MPS to promote terminal Hair growth in adult women with self-perceived thinning Hair associated with poor diet, stress, hormonal influences, or abnormal menstrual cycles. Adult women with thinning Hair were randomized to receive MPS () or placebo () twice daily for 90 days. Digital images were obtained from a 4 cm2 area scalp target area. Each subject’s Hair was washed and shed Hairs were collected and counted. After 90 days, these measures were repeated and subjects completed Quality of Life and Self-Assessment Questionnaires. MPS-treated subjects achieved a significant increase in the number of terminal Hairs within the target area () which was significantly greater than placebo (). MPS use also resulted in significantly less Hair Shedding () and higher total Self-Assessment () and Quality of Life Questionnaires scores (). There were no reported adverse events. MPS promotes Hair growth and decreases Hair loss in women suffering from temporary thinning Hair. This trial is registered with ClinicalTrials.gov Identifier: NCT02297360.
Antonella Tosti - One of the best experts on this subject based on the ideXlab platform.
-
Effects of a New Topical Treatment Containing Several Hair Growth Promoters in Women with Early Female Pattern Hair Loss
Skin appendage disorders, 2018Co-Authors: Colombina Vincenzi, Antonella Tosti, Benedetta Marisaldi, Brijeshkumar PatelAbstract:Background: Female pattern Hair loss (FPHL) is increasing ly common and often presents with Hair Shedding. Spec tral.DNC-N® contains anti-inflammatory actives and Hair growth promoters. Objectives: To assess the efficacy and tolerability of Spectral DNC-N® (DS Laboratories, Inc.) in women with early FPHL and excessive Shedding. Methods: Forty-nine patients were treated with Spectral DNC-N®, applied twice daily for 3 months; 28 patients were included in the 3-month treatment extension. Efficacy assessments included the degree of Hair Shedding using the validated Hair Shedding visual scale, Hair mass index (HMI), and photographic evaluation. Results: There was a statistically significant decrease in Hair Shedding and a corresponding increase in HMI by month 3, which was maintained through month 6. The mean investigator-assessed Hair Shedding score decreased from 3.5 to 2.0 and the Hair mass increased from 75.8 to 84.3 mm2/cm2 by month 3 (both p < 0.01 compared with baseline). By month 6, the Hair Shedding score was reduced to 1.6 and the Hair mass was maintained. Most patients (75%) showed an increase in global Hair density. Conclusions: Spectral.DNC-N® significantly reduced Hair Shedding, with a corresponding increase in Hair mass and density. These effects were already evident after 3 months’ treatment and further improved in those patients who continued treatment to month 6. Tolerability was good and patient satisfaction levels were high.
-
The Hair Shedding Visual Scale: A Quick Tool to Assess Hair Loss in Women
Dermatology and Therapy, 2017Co-Authors: Maria Abril Martinez-velasco, Norma Elizabeth Vázquez-herrera, Austin J. Maddy, Daniel Asz-sigall, Antonella TostiAbstract:Introduction Hair Shedding is a common consequence of the normal Hair cycle that changes with internal and external factors. Female pattern Hair loss (FPHL) is difficult to assess in terms of Shedding severity as the conscious perception of Hair Shedding varies according to each individual, and most utilized methods are semi-invasive or very time consuming. In this study, we establish and validate a Hair-Shedding scale for women with thick Hair of different lengths. Methods A visual analog scale was developed for thick Hair of short, medium, and long lengths by dividing a bundle of Hairs of each length into nine piles of increasing Hair amount that were then photographed and arranged in order of size. Twenty women with no FPHL with each length of Hair (60 total) were asked to select the photographed Hair bundle that best correlated with the amount of Hair they shed on an average day. A total of 94 women with FPHL with excessive Shedding were then asked to repeat the same process. Results Women with no FPHL and short, medium and long Hair had mean Shedding scores of 2.5, 2.35 and 2.4, respectively. Women with FPHL and short, medium and long Hair had mean Shedding scores of 7.25, 7.0 and 7.14, respectively. Statistically significant Spearman’s ρ coefficient and κ coefficient demonstrated correlation and inter-observer reliability. Conclusion Our results show that women with FPHL not only shed considerable Hair more than women with no FPHL, but that this Hair-Shedding visual scale is a fast and effective method of evaluating Hair-Shedding amounts in an office setting.
-
the Hair Shedding visual scale a quick tool to assess Hair loss in women
Dermatologic Therapy, 2017Co-Authors: Maria Abril Martinezvelasco, Austin J. Maddy, Norma Elizabeth Vazquezherrera, Daniel Aszsigall, Antonella TostiAbstract:Hair Shedding is a common consequence of the normal Hair cycle that changes with internal and external factors. Female pattern Hair loss (FPHL) is difficult to assess in terms of Shedding severity as the conscious perception of Hair Shedding varies according to each individual, and most utilized methods are semi-invasive or very time consuming. In this study, we establish and validate a Hair-Shedding scale for women with thick Hair of different lengths. A visual analog scale was developed for thick Hair of short, medium, and long lengths by dividing a bundle of Hairs of each length into nine piles of increasing Hair amount that were then photographed and arranged in order of size. Twenty women with no FPHL with each length of Hair (60 total) were asked to select the photographed Hair bundle that best correlated with the amount of Hair they shed on an average day. A total of 94 women with FPHL with excessive Shedding were then asked to repeat the same process. Women with no FPHL and short, medium and long Hair had mean Shedding scores of 2.5, 2.35 and 2.4, respectively. Women with FPHL and short, medium and long Hair had mean Shedding scores of 7.25, 7.0 and 7.14, respectively. Statistically significant Spearman’s ρ coefficient and κ coefficient demonstrated correlation and inter-observer reliability. Our results show that women with FPHL not only shed considerable Hair more than women with no FPHL, but that this Hair-Shedding visual scale is a fast and effective method of evaluating Hair-Shedding amounts in an office setting.
-
The Hair Shedding Visual Scale: A Quick Tool to Assess Hair Loss in Women
Dermatologic Therapy, 2017Co-Authors: Maria Abril Martinez-velasco, Norma Elizabeth Vázquez-herrera, Austin J. Maddy, Daniel Asz-sigall, Antonella TostiAbstract:Introduction Hair Shedding is a common consequence of the normal Hair cycle that changes with internal and external factors. Female pattern Hair loss (FPHL) is difficult to assess in terms of Shedding severity as the conscious perception of Hair Shedding varies according to each individual, and most utilized methods are semi-invasive or very time consuming. In this study, we establish and validate a Hair-Shedding scale for women with thick Hair of different lengths.
Edwin Nematian - One of the best experts on this subject based on the ideXlab platform.
-
Increased Hair Shedding May be Associated with the Presence of Pityrosporum ovale
American Journal of Clinical Dermatology, 2006Co-Authors: Javad Nematian, Mehrdad Ravaghi, Ali Gholamrezanezhad, Edwin NematianAbstract:Background and objective : Although the available data show that Hair loss is an important cosmetic problem worldwide, the pathogenesis of common Hair Shedding is not fully understood. The aim of this study was to evaluate the association between Hair Shedding and cutaneous Malassezia infection. Malassezia fungi have been the suspected cause of dandruff for more than a century. Previously referred to as Pityrosporum ovale or P. orbiculare , these fungi are now known to consist of at least seven species. Methods : Over a 4-year period, we obtained 300 Hair samples from medical students. Based on the clinical history and a Hair-pull test, the participants were divided into two groups: normal subjects and subjects with Hair Shedding. The students’ scalp skin was gently scraped, smeared on a slide, colored by methylene blue, and observed under 10× magnification. Results : All participants who had positive smears with ≥3 P. ovale organisms per low-power microscopic field (10×) were defined as ‘ecarriers.’ Seventy-six percent of students were Malassezia carriers. The prevalence of positive smears was significantly higher among subjects with Hair Shedding than among normal subjects (89.92% vs 9.52%, p < 0.001). Furthermore, participants with positive smears had a significantly higher frequency of Hair loss complaints and positive Hair-pull tests. Conclusion : The proportion of subjects who were carriers of Malassezia yeasts was significantly higher in the group with Hair Shedding, and our results therefore raise the possibility of a relationship between this unicellular organism and Hair loss. Our study findings should be explored in a larger series of patients.
-
increased Hair Shedding may be associated with the presence of pityrosporum ovale
American Journal of Clinical Dermatology, 2006Co-Authors: Javad Nematian, Mehrdad Ravaghi, Ali Gholamrezanezhad, Edwin NematianAbstract:Background and objective: Although the available data show that Hair loss is an important cosmetic problem worldwide, the pathogenesis of common Hair Shedding is not fully understood. The aim of this study was to evaluate the association between Hair Shedding and cutaneous Malassezia infection. Malassezia fungi have been the suspected cause of dandruff for more than a century. Previously referred to as Pityrosporum ovale or P. orbiculare, these fungi are now known to consist of at least seven species.
Ronald L Rizer - One of the best experts on this subject based on the ideXlab platform.
-
a marine protein based dietary supplement for subclinical Hair thinning loss results of a multisite double blind placebo controlled clinical trial
International Journal of Trichology, 2015Co-Authors: Ronald L Rizer, Thomas J Stephens, James H Herndon, Brian R Sperber, James Murphy, Glynis AblonAbstract:Introduction: Since skin and Hair quality are potent vitality signals, and Hair growth deficiency can cause significant psychological morbidity. In addition to clearly-defined Hair loss disorders, milder forms of Hair thinning or Hair loss appear to be increasingly common, with a suggestion that sub-optimal diets and stressful lifestyles may be involved. Methods: Here we assess the value of a dietary marine-extract based dietary supplement in premenopausal women with subclinical Hair thinning or Hair loss conditions. This multi-site, randomized double-blind, placebo-controlled clinical trial was conducted with impact on Hair Shedding rate and Hair fiber diameter (assessed by phototrichogram) as primary end points upon consumption of the oral supplement compared to a placebo. A total of 96 eligible female subjects were enrolled aged 21-55 years of age from Asian, Caucasian, and Hispanic ethnic backgrounds. Results: This study showed that Hair Shedding was significantly reduced in the first 3-6 months of daily consumption of the oral supplement. Moreover, phototrichogram image analysis revealed a statistically significant increase in the mean vellus-like Hair diameter after 6 months of supplement consumption, when compared to the mean vellus-like Hair diameters measured at baseline. Discussion: These results support the view that a nutritional supplement approach may be useful for women in this age group to deal with subclinical Hair thinning or Hair loss conditions, and those components of this marine extract-based oral supplement may be a useful adjunct.
-
A marine protein-based dietary supplement for subclinical Hair thinning/loss: Results of a multisite, double-blind, placebo-controlled clinical trial
International Journal of Trichology, 2015Co-Authors: Ronald L Rizer, Thomas J Stephens, James H Herndon, Brian R Sperber, James Murphy, Glynis AblonAbstract:Introduction: Since skin and Hair quality are potent vitality signals, and Hair growth deficiency can cause significant psychological morbidity. In addition to clearly-defined Hair loss disorders, milder forms of Hair thinning or Hair loss appear to be increasingly common, with a suggestion that sub-optimal diets and stressful lifestyles may be involved. Methods: Here we assess the value of a dietary marine-extract based dietary supplement in premenopausal women with subclinical Hair thinning or Hair loss conditions. This multi-site, randomized double-blind, placebo-controlled clinical trial was conducted with impact on Hair Shedding rate and Hair fiber diameter (assessed by phototrichogram) as primary end points upon consumption of the oral supplement compared to a placebo. A total of 96 eligible female subjects were enrolled aged 21-55 years of age from Asian, Caucasian, and Hispanic ethnic backgrounds. Results: This study showed that Hair Shedding was significantly reduced in the first 3-6 months of daily consumption of the oral supplement. Moreover, phototrichogram image analysis revealed a statistically significant increase in the mean vellus-like Hair diameter after 6 months of supplement consumption, when compared to the mean vellus-like Hair diameters measured at baseline. Discussion: These results support the view that a nutritional supplement approach may be useful for women in this age group to deal with subclinical Hair thinning or Hair loss conditions, and those components of this marine extract-based oral supplement may be a useful adjunct.
